Update

Press Release

December 15, 2020 Notice of license agreement
We announced that it entered into a license agreement with Ono Pharmaceutical Co., Ltd. for CTX-177, Chordia’s MALT1 inhibitor, as well as its other related compounds. Under the terms of the agreement, Chordia will grant exclusive rights to develop, manufacture and commercialize CTX-177 and other related compounds globally. Chordia will receive a one-time upfront payment and near-term development milestone totaling JPY3.3 billion (upfront JPY0.8 billion, and JPY2.5 billion at starting phase 1 clinical study), and up to an additional JPY49.6 billion if certain development and commercial milestones are achieved.